Return on Assets (ROA)
since 2018
Paying user area
Try for free
Moderna Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Total Asset Turnover since 2018
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Moderna Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Moderna Inc., ROA, long-term trends, calculation
| ROA | = | 100 | × | Net income (loss)1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | = | 100 | × | ÷ | |||
| Dec 31, 2022 | = | 100 | × | ÷ | |||
| Dec 31, 2021 | = | 100 | × | ÷ | |||
| Dec 31, 2020 | = | 100 | × | ÷ | |||
| Dec 31, 2019 | = | 100 | × | ÷ | |||
| Dec 31, 2018 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$ in millions
- Net Income (Loss) Trend
- The net income of the company exhibited significant volatility over the observed period. Initially, the company reported consistent losses from 2018 through 2020, with the loss deepening from -385 million USD in 2018 to -747 million USD in 2020. A marked positive turnaround occurred in 2021, when net income surged to 12,202 million USD, followed by a decrease to 8,362 million USD in 2022. However, in 2023, the company returned to a loss position, recording a net loss of -4,714 million USD.
- Total Assets Trend
- Total assets showed substantial growth from 2018 to 2022, increasing from 1,962 million USD in 2018 to a peak of 25,858 million USD in 2022. This dramatic rise reflects a significant accumulation of assets during these years. However, in 2023, assets declined to 18,426 million USD, indicating a contraction after the prior peak.
- Return on Assets (ROA) Trend
- The return on assets mirrored the fluctuations seen in net income. Negative ROA values persisted from 2018 to 2020, with a notable extreme low of -32.34% in 2019. A sharp improvement was observed in 2021 with ROA reaching 49.46%, coinciding with the large net income gain, followed by a reduced positive ROA of 32.34% in 2022. In 2023, ROA again turned negative, declining to -25.58%, consistent with the return to net losses and reduced asset base.
- Summary Insights
- The financial data indicates a company undergoing a period of transformation with high volatility in profitability and asset size. The surge in net income and assets between 2020 and 2022 suggests successful expansion or monetization activities during this period. However, the reversion to losses and asset reduction in 2023 may signal challenges in sustaining prior gains or increased costs. The ROA trend aligns closely with profitability shifts, emphasizing the company's fluctuating efficiency in asset utilization over the years reviewed.
Comparison to Competitors
Moderna Inc., ROA, long-term trends, comparison to competitors
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | |||||||||||||
| Dec 31, 2022 | |||||||||||||
| Dec 31, 2021 | |||||||||||||
| Dec 31, 2020 | |||||||||||||
| Dec 31, 2019 | |||||||||||||
| Dec 31, 2018 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Moderna Inc., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Moderna Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2023 | ||
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 31, 2019 | ||
| Dec 31, 2018 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Industry (Health Care)
Moderna Inc., ROA, long-term trends, comparison to industry (health care)
| Moderna Inc. | Health Care | |
|---|---|---|
| Dec 31, 2023 | ||
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 31, 2019 | ||
| Dec 31, 2018 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).